Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1791418 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2HTR6MAPK1TRPV4POLB | |
| SCHEMBL6069951 | 0.83 | CA2 (0.46) | CA12CA1CA2CA9PKM | |
| SCHEMBL27177203 | 0.83 | ELANE (0.39) | SMN1; SMN2HTR6MAPK1TRPV4POLB | |
| SCHEMBL10405334 | 0.83 | ALDH1A1 (0.37) | SMN1; SMN2HTR6MAPK1TRPV4POLB | |
| SCHEMBL27566617 | 0.81 | SOAT1 (0.34) | SMN1; SMN2HTR6POLBTSHRL3MBTL1 | |
| SCHEMBL5447959 | 0.80 | TSHR (0.44) | SMN1; SMN2MAPK1POLBTSHRKDM4E | |
| SCHEMBL5451015 | 0.78 | HTR6 (0.65) | HTR6PKMKDM4EUSP2GAA | |
| SCHEMBL6199512 | 0.77 | L3MBTL1 (0.33) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL9740475 | 0.76 | PTPN1 (0.35) | SMN1; SMN2HTR6MAPK1POLBTSHR | |
| SCHEMBL1448807 | 0.74 | L3MBTL1 (0.44) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1934111-A | Heteroaryl-fused pyrazolo derivatives | ROCHE PALO ALTO LLC (CH) | 2007-03-21 | — | — | CN | claimed |
| CN-108473439-B | Pyrazolone derivatives as nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2022-03-15 | — | — | CN | disclosed |
| US-10723704-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-3148972-B1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10292973-B2 | Covalent irreversible inhibitors of USP7 as anti-cancer agents | PROGENRA, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180318308-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2018-11-08 | — | — | US | disclosed |
| WO-2018160944-A1 | AZOLE COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE USP7 INHIBITORS | PROGENRA, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| EP-3365328-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9717717-B1 | Methods of treating cancer through the inhibition of USP7 and immune system modulation | PROGENRA, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| WO-2017070081-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-3148972-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2017023684-A2 | COVALENT IRREVERSIBLE INHIBITORS OF USP7 AS ANTI-CANCER AGENTS | PROGENRA, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2015183839-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| CN-1934111-A | Heteroaryl-fused pyrazolo derivatives | ROCHE PALO ALTO LLC (CH) | 2007-03-21 | — | — | CN | disclosed |
| US-6043263-A | (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-28 | — | — | US | disclosed |
| WO-1998008844-A1 | THIAZOLE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE-IV | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723704-B2 | Pyrazolone derivatives as nitroxyl donors | TNNI3, PFKP, NOX5 | SMN1; SMN2 1078/4885HTR6 1226/4885MAPK1 3982/4885 |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | SMN1; SMN2 1078/4885HTR6 1226/4885MAPK1 3982/4885 |
| US-20180318308-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | SMN1; SMN2 1078/4885HTR6 1226/4885MAPK1 3982/4885 |
| US-10292973-B2 | Covalent irreversible inhibitors of USP7 as anti-cancer agents | USP7, USP2, USP28 | SMN1; SMN2 4705/4885HTR6 4595/4885MAPK1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.